| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-08-0374 |
| P698 | PubMed publication ID | 18974395 |
| P2093 | author name string | Neal Rosen | |
| James G Christensen | |||
| David B Solit | |||
| Manish Shah | |||
| Martin R Weiser | |||
| Thomas Bachleitner-Hofmann | |||
| Zhaoshi Zeng | |||
| Lin Song | |||
| Chin-Tung Chen | |||
| Laura Tang | |||
| Mark Y Sun | |||
| P2860 | cites work | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| P433 | issue | 11 | |
| P304 | page(s) | 3499-3508 | |
| P577 | publication date | 2008-10-30 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells | |
| P478 | volume | 7 |
| Q38702212 | A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach |
| Q44303811 | A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer |
| Q28480605 | A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation |
| Q39133025 | A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity |
| Q42081770 | Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency |
| Q33942266 | Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. |
| Q24633986 | An overview of the c-MET signaling pathway |
| Q33649756 | Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review |
| Q35688071 | Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition |
| Q39841653 | Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors |
| Q47552119 | Clinical Significance of Glycoprotein Non-metastatic B and Its Association with EGFR/HER2 in Gastrointestinal Cancer |
| Q26776190 | Clinical significance of MET in gastric cancer |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q38751892 | Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort |
| Q35110418 | Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells |
| Q24338635 | EGFR/Met association regulates EGFR TKI resistance in breast cancer |
| Q38383859 | Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial |
| Q37893414 | Emerging antibody combinations in oncology |
| Q38284597 | Emerging mAbs for the treatment of esophagogastric cancer |
| Q33769437 | Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors |
| Q38110962 | Emerging tyrosine kinase inhibitors for esophageal cancer |
| Q28252845 | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors |
| Q39528185 | Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks |
| Q37591176 | Gastric cancer-molecular and clinical dimensions |
| Q34832117 | Genetic modifiers of EGFR dependence in non-small cell lung cancer |
| Q55071600 | HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. |
| Q34550898 | HGF rescues colorectal cancer cells from EGFR inhibition via MET activation |
| Q37696629 | Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab |
| Q34478374 | Increased MET Gene Copy Number but Not mRNA Level Predicts Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer |
| Q35112834 | Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors |
| Q36436763 | Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer |
| Q64110551 | Low Expression of hsa_circ_0018069 in Human Bladder Cancer and Its Clinical Significance |
| Q39413378 | MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells |
| Q36984821 | MET amplification as a potential therapeutic target in gastric cancer. |
| Q36949256 | MET expression and amplification in patients with localized gastric cancer |
| Q36484469 | MUC1 drives c-Met-dependent migration and scattering. |
| Q28077785 | Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing |
| Q34613189 | Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis |
| Q47967299 | Met, IGF1R, and other new targets in upper GI malignancies |
| Q33828409 | Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy |
| Q35525305 | Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors |
| Q41127315 | New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors |
| Q39453553 | Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies |
| Q27320322 | Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer |
| Q35006543 | Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells. |
| Q33638654 | Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status |
| Q50985091 | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. |
| Q34963286 | Receptor-type protein tyrosine phosphatase beta (RPTP-beta) directly dephosphorylates and regulates hepatocyte growth factor receptor (HGFR/Met) function |
| Q39404068 | Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines |
| Q38424220 | Role of c-mesenchymal-epithelial transition pathway in gastric cancer. |
| Q38912433 | SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer |
| Q34094632 | Small molecule c-Met kinase inhibitors: a review of recent patents |
| Q35129076 | Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy |
| Q37925131 | Targeted therapies in the treatment of gastric cancer. |
| Q36039645 | Targeted therapy for esophagogastric cancers: a review |
| Q35863874 | Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? |
| Q37405633 | Targeting EGFR resistance networks in head and neck cancer. |
| Q37688459 | Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. |
| Q37539304 | Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q55069791 | The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. |
| Q37165851 | The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases |
| Q37567784 | Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). |
| Q50985108 | c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences. |
Search more.